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Abstract
There has been considerable debate on the extent to which future costs should be included in cost-effectiveness analyses of 
health technologies. In this article, we summarize the theoretical debates and empirical research in this area and highlight 
the conclusions that can be drawn for current practice. For future related and future unrelated medical costs, the literature 
suggests that inclusion is required to obtain optimal outcomes from available resources. This conclusion does not depend 
on the perspective adopted by the decision maker. Future non-medical costs are only relevant when adopting a societal 
perspective; these should be included if the benefits of non-medical consumption and production are also included in the 
evaluation. Whether this is the case currently remains unclear, given that benefits are typically quantified in quality-adjusted 
life-years and only limited research has been performed on the extent to which these (implicitly) capture benefits beyond 
health. Empirical research has shown that the impact of including future costs can be large, and that estimation of such costs 
is feasible. In practice, however, future unrelated medical costs and future unrelated non-medical consumption costs are 
typically excluded from economic evaluations. This is explicitly prescribed in some pharmacoeconomic guidelines. Further 
research is warranted on the development and improvement of methods for the estimation of future costs. Standardization of 
methods is needed to enhance the practical applicability of inclusion for the analyst and the comparability of the outcomes 
of different studies. For future non-medical costs, further research is also needed on the extent to which benefits related to 
this spending are captured in the measurement and valuation of health benefits, and how to broaden the scope of the evalu-
ation if they are not sufficiently captured.
Key Points for Decision Makers 
When an intervention prolongs life, this leads to addi-
tional costs in added life-years. Including the additional 
medical costs in economic evaluations is required, under 
reasonable assumptions, to allow optimal decisions, both 
from a healthcare and societal perspective.
Knowledge on how to estimate future (unrelated) medi-
cal costs has improved. Important challenges for their 
systematic inclusion in economic evaluations are chang-
ing pharmacoeconomic guidelines to allow or prescribe 
inclusion (rather than exclusion) and lowering the practi-
cal difficulties for doing so.
The inclusion of future non-medical costs is hampered 
by both theoretical and empirical challenges. The ben-
efits of future non-medical consumption and productivity 
may currently not be comprehensively and systematically 
included in cost-effectiveness analyses. This is a require-
ment for including these costs.
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1 Introduction
Cost-effectiveness analyses are increasingly used to guide 
pricing and reimbursement decisions in healthcare [1]. The 
analytical approach most frequently applied is a cost-utility 
analysis, wherein outcomes are quantified in quality-adjusted 
life-years (QALYs). The results of the analysis are typi-
cally summarized in an incremental cost-effectiveness ratio 
(ICER), the ratio of additional costs to additional benefits of 
a new intervention compared to an appropriate alternative. 
A fundamental issue within a cost-effectiveness analysis, 
which is unresolved to date, is the extent to which future 
costs should be included in the ICER [2, 3]. Future costs 
(also referred to as ‘survivor costs’) are the costs that arise 
during the life-years that would not have been lived with-
out a life-extending intervention. These costs are typically 
classified into future related medical costs, future unrelated 
medical costs, and future non-medical costs.1
Future related medical costs are costs for treatments in 
life-years gained that are directly related to the disease that 
is being treated with the life-extending treatment. When, 
for instance, an intervention to treat a heart-attack success-
fully extends life, costs for routinely visiting a cardiolo-
gist thereafter would count as future related medical costs. 
Future unrelated medical costs are only a consequence of the 
life-extending intervention through its effect on life expec-
tancy. Costs for treating a broken leg or severe influenza 
after surviving a heart attack would be examples of these 
costs. Future non-medical costs comprise future net non-
medical resource use. These future non-medical costs can be 
obtained by subtracting productivity gains as a result of the 
ability to work longer when life is extended from the costs 
of non-medical consumption during the life-years gained. 
Examples of such future non-medical consumption costs are 
travel expenditures and costs for housing and food during 
the life-years gained.
Although none of the future costs would arise without 
the life-saving intervention, not all of these costs would 
generally be included in cost-effectiveness analyses of life-
prolonging interventions. The exclusion of some of the costs 
can be justified by the perspective adopted by the decision 
maker. The aim of a decision maker adopting a healthcare 
perspective, for example, is typically assumed to be the 
maximization of health or health-related utility under the 
constraint of the healthcare budget. Broader welfare implica-
tions including future non-medical costs are then generally 
ignored. In contrast, a decision maker adopting a societal 
perspective is typically assumed to aim to maximize social 
welfare, often described as some (weighted) aggregation 
of individual welfare, under the constraint of total societal 
resources.2 For such a decision maker, broader welfare eco-
nomic implications beyond healthcare are relevant, and are 
generally taken into account in an economic evaluation [4].
The extent to which future costs should be included 
in a cost-effectiveness analysis, considering the decision 
maker’s perspective, has been frequently debated [2, 5–21]. 
Although progress has been made, diverging approaches and 
viewpoints continue to exist in both theoretical and practi-
cal contributions in this area. To contribute to appropriate 
methods, to increase validity, consistency, and comparabil-
ity of results, our aims in this article are threefold. First, to 
highlight past theoretical debates and empirical research on 
the inclusion of future costs in a cost-effectiveness analysis; 
second, to clarify which issues within these debates are unre-
solved to date; and third, to indicate future research needed 
in this area.
2  Future Medical Costs
In this section, we discuss the inclusion of future medical 
costs. We start with the discussion of the theoretical debates 
and then elaborate on the empirical research.
2.1  Theoretical Debates
In the development of methodological guidance for cost-
effectiveness analyses, mathematical models have played 
an important role. For instance, the decision rule to adopt 
an intervention only when the ICER is lower than a cost-
effectiveness threshold has been derived from a mathemati-
cal model with a clearly defined objective and several con-
straints [23]. Such models have also been developed and 
used to address the question whether future costs should be 
included in cost-effectiveness analyses.3
Van Baal and colleagues [19], for instance, set up a math-
ematical model describing a decision maker who wants to 
1 Future non-medical costs could also be categorized into future 
related and unrelated costs, to the same degree as future medical 
costs. However, in concordance with previous literature, we will not 
make this distinction and label all these costs here as future non-med-
ical costs.
2 Note that adopting a societal perspective is not synonymous with 
taking a welfarist approach, which restricts welfare information to 
solely (individual) utilities. Extra-welfarism, allowing broader defi-
nitions of welfare including for example capabilities, is fully com-
patible with taking a societal perspective [22]. Hence, the issues 
addressed in this article are relevant for both approaches.
3 In these models, future medical costs are specified as related or 
unrelated on a cost level (expenditures conditional on survival, which 
do not change with an increase in the quantities of the intervention 
consumed, are unrelated). In practice, future medical costs are typi-
cally specified as related or unrelated on the level of the disease to be 
treated.
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maximize QALYs given a fixed healthcare budget. They 
concluded that both future related medical costs and future 
unrelated medical costs should be included in a cost-effec-
tiveness analysis to maximize the number of QALYs gained 
from available resources. The explanation is that given a 
fixed healthcare budget, life-prolonging interventions neces-
sarily result in a lower budget per person for healthcare in 
the future. Hence, life-prolonging interventions have real 
health opportunity costs by leaving less budget for others. 
Excluding future unrelated medical costs therefore leads to 
an underestimation of the opportunity costs of life-extending 
interventions. As a consequence, ignoring these costs could 
result in care being adopted that is actually less cost effec-
tive than the care that it displaces or prevents from being 
funded. Hence, inclusion of future unrelated medical costs 
can lead to different decisions and ultimately leads to more 
(health) benefits.
For decision making from the societal perspective, several 
competing mathematical models have been proposed that 
have implications for the inclusion of future medical costs. 
The assumptions underlying these models are typically 
of major importance for the interpretation and real-world 
relevance of the results. For instance, Garber and Phelps 
[5] developed a model from which the welfare-optimizing 
decision rule included future related and unrelated medical 
costs in the ICER. However, according to their model, future 
unrelated medical costs could be excluded without affecting 
the relative ranking of cost effectiveness of alternatives. This 
makes exclusion possible provided practice is consistent and 
the value of the cost-effectiveness threshold appropriately 
adjusted [5]. Crucial assumptions in their model that were 
required to arrive at these conclusions were that earnings 
and consumption profiles (both medical and non-medical) do 
not vary by age and that at every age individuals exactly con-
sume what they produce. These assumptions are difficult to 
justify, given the observed age patterns in healthcare use and 
net resource use [6, 24]. Furthermore, the trade-off between 
improvement of quality of life and improvement of length 
of life was not properly accounted for in this model. This 
is relevant because interventions that only increase qual-
ity of life are not affected by the inclusion or exclusion of 
costs in life-years gained (as survival is unaffected). Ignoring 
future costs for life-prolonging interventions thus distorts 
their comparison to interventions that improve quality of 
life. This leads to biased decisions in favor of life-prolonging 
interventions.
Meltzer [6] constructed a more general model with less 
restrictive assumptions, and, based on that, concluded that 
the welfare-optimizing decision rule necessarily includes 
both future related medical costs and future unrelated medi-
cal costs in the ICER. As future unrelated medical costs can 
vary under different conditions, excluding these may affect 
the relative ranking of cost effectiveness of alternatives, 
and consequently lead to different decisions on the care to 
provide.
Later, Lee presented a model implying that the welfare-
optimizing decision rule need not include future unrelated 
medical costs. Furthermore, including these costs would, 
according to this model, lead to suboptimal outcomes for 
society [14]. His model was subsequently criticized because 
it employed similar assumptions as Garber and Phelps by 
ignoring survival probabilities in the budget constraint. 
Therefore, ignoring this essentially implies that these costs 
were not meaningfully included in the model to begin with 
[15]. Feenstra and colleagues [16], in response to Lee, 
showed that proper inclusion of the probability of survival in 
the budget constraint, and thereby capturing the increase in 
future unrelated medical expenditures as a necessary conse-
quence of increased life expectancy, leads to the conclusion 
that future unrelated medical costs should be included in a 
cost-effectiveness analysis. These results support the results 
earlier found by Meltzer [6, 15].
Conversely, some have argued that new treatments should 
be evaluated in isolation (excluding both costs and benefits 
of unrelated care) [4, 25]. In this line of reasoning, it is 
claimed that future unrelated medical care is not a neces-
sary consequence of the life-prolonging intervention because 
no irreversible commitment to obtain future unrelated care 
is made when adopting it [4]. Although intuitively appeal-
ing, the commitment argument does not provide a rationale 
why we should include lifetime consequences of a decision 
in terms of healthcare use for related diseases (like the car-
diologist’s visits in the introduction) but not for unrelated 
diseases (like the broken leg). For both disease categories, 
it is often unclear what the exact commitments will be in 
the future (although it is likely that there will be commit-
ments). More importantly, van Baal and colleagues dem-
onstrated that consistently excluding the costs and benefits 
of unrelated care in general pushes the ICER upwards and 
results in suboptimal decisions [12]. The reason for this 
is that unrelated medical care is usually a mix of different 
interventions and the cost effectiveness of unrelated medical 
care will then be some sort of average return to healthcare 
expenditures, which on average is lower than the threshold. 
If indeed future unrelated medical care is cost effective, the 
inclusion of both costs and benefits can never push an ICER 
above the threshold.
It should also be emphasized that although the inclu-
sion of future unrelated medical costs has been disputed, 
the benefits related to this spending are generally already 
included in cost-effectiveness analyses. The quality of life 
and life expectancy upon which estimates of benefits of life-
prolonging interventions are based are typically observed in 
patients also receiving unrelated medical care. This implies 
that the benefits of unrelated medical costs are projected 
in the estimations of the QALY gains of a life-extending 
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intervention. Childhood vaccination may, for example, 
prevent early death. However, quality of life and expected 
survival in added life-years depend on the provision of unre-
lated healthcare during these years and estimates thereof 
typically obtained in people receiving unrelated care. To 
exclude costs but include benefits of unrelated future medi-
cal care would of course be inconsistent.
In that context, Nyman developed rules for internal con-
sistency to determine which costs should be included in a 
cost-effectiveness analysis given the benefits included. These 
rules require that all costs required to produce projected ben-
efits should be included, as well as those that are causally 
related to the intervention, even when they do not yield addi-
tional benefits. Given current practice, internal consistency 
thus requires that future unrelated medical costs should be 
included because benefits thereof are captured in the pro-
jected QALY gains [7, 12].
It needs to be noted that internal consistency could also 
be achieved by excluding both costs and benefits of unrelated 
care. Doing so however requires disentangling related and 
unrelated costs and benefits, which is practically difficult, if 
not impossible [12, 20]. Benefits from interventions would 
then for example need to be estimated under the assump-
tion that patients would not receive any unrelated care. It 
appears highly difficult to practically estimate the quality of 
life of patients under such assumptions. Furthermore, it is 
not always clear or known which costs are actually related 
or unrelated [26, 27]. Additionally, if the aim of an eco-
nomic evaluation is to meaningfully inform healthcare deci-
sion makers, inclusion of future unrelated medical costs and 
their benefits seems most appropriate (also referred to as the 
external consistency argument) [2, 12, 20]. To illustrate this, 
take the example of childhood vaccination. It seems rather 
inconceivable that people who live longer because of child-
hood vaccination would be denied standard future care on 
that ground. Nor is it clear how one would estimate their life 
expectancy and quality of life without future care, or what 
the practical relevance would be of doing so.
Summarizing, the theoretical work in this area suggests 
that under the most reasonable assumptions it is necessary 
to include both future related medical costs and future unre-
lated medical costs in the ICER to obtain optimal decisions, 
in line with the decision maker’s objectives. This conclusion 
holds, regardless of the perspective that is adopted by the 
decision maker. Inclusion is optimal as well as internally 
and externally consistent.
2.2  Empirical Research
Practical difficulties in the estimation of future unrelated 
medical costs and the burden that having to include these 
costs may place on analysts have been mentioned as argu-
ments not to include these costs in a cost-effectiveness 
analysis [3, 25, 28]. However, methods have been developed 
to facilitate the estimation of future medical costs, which 
was possible given the knowledge on the effect of aging on 
healthcare expenditures [29]. It would be an unsurmount-
able task to predict the risk of all unrelated diseases and 
link these predictions to costs to estimate future unrelated 
medical costs. Therefore, rather than modeling all these indi-
vidual diseases explicitly, the starting point for the estima-
tion of future unrelated medical costs is typically estimates 
of medical spending by age, which comprise spending on 
all sorts of diseases [6]. Such an approach is similar to how 
economic modeling studies usually deal with other causes 
of death, as well as estimates of quality of life by age (which 
are included to deal with the fact that mortality risk increases 
with age and quality of life generally decreases) [30]. Age- 
and sex-specific per-capita medical spending can then be 
linked to survival curves to estimate future unrelated medi-
cal costs. In general, there is no correction for the fact that 
per-capita spending includes spending for related diseases 
unless the related disease(s) represent a large part of health 
spending. For instance, several modeling studies focusing 
on smoking and obesity do correct per-capita spending for 
the cost of related diseases when estimating future unrelated 
medical costs [31–33].
Further refinements in estimating future medical con-
sumption have been made by taking into account the obser-
vation that healthcare spending is usually concentrated in the 
last phase of life [34, 35]. This also typically affects how age 
influences medical expenditures because part of the effect of 
aging may be owing to the costs of dying (and older people 
have higher probabilities of dying) [36]. Given that every-
body only dies once, the impact of unrelated medical costs 
on the ICER is less strong when one accounts for the higher 
spending in the last year of life [34, 37].
In the Netherlands, a tool was developed that facilitates 
the inclusion of unrelated medical costs in a standardized 
manner, accounting for the high spending in the last year 
of life and allowing for the correction for costs of related 
diseases [35]. For other countries, such tools do not yet exist 
but estimates of spending by age, sex, and disease have been 
produced for several countries, which would allow the crea-
tion of such a tool or other comparable guidance, also for 
those countries. For instance, several studies have illustrated 
how to estimate future unrelated medical costs for the UK 
[19, 38–40].
Of course, the exact nature and height of future health-
care spending is uncertain, and increasingly so when it is 
further ahead in the future. A common assumption in stud-
ies addressing future unrelated medical costs is that future 
spending patterns resemble current healthcare spending pat-
terns. While this is an assumption that need not completely 
hold, it seems a reasonable starting point for estimation 
(and better than estimates of zero) and is consistent with the 
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types of assumptions commonly made in practical economic 
evaluations. In these evaluations, for instance, the estimates 
of the impact of individual interventions on future health 
and healthcare also assume the current standard of care [20].
Estimates of the impact of including future unrelated 
medical costs for specific patients and treatments have 
revealed that the inclusion of future unrelated medical costs 
can significantly affect the cost effectiveness of interven-
tions [12, 19, 26, 41–45]. These findings refute the argu-
ment that future unrelated medical costs are negligible and 
can therefore be ignored [25, 28]. Moreover, these studies 
revealed large differences in the changes in ICERs as a result 
of inclusion depending on the age of the patients, following 
from the pattern that healthcare consumption is typically 
higher for people at higher ages. As a result, including the 
future unrelated medical costs has more impact when people 
reach higher ages.
Textbox 1 describes an example of a Dutch study in 
which including future unrelated medical costs signifi-
cantly affected cost-effectiveness estimates. During the 
submission process of the new intervention, Dutch phar-
macoeconomic guidelines were updated and future unre-
lated medical costs had to be included. Because of this, a 
full analysis was performed both including and excluding 
future unrelated medical costs, [46] highlighting the impact 
of inclusion.
In the Netherlands, cost effectiveness is judged against 
a threshold ranging from €20,000 to €80,000, for which 
the height depends on the principle of proportional short-
fall. For this treatment, a threshold of €50,000 applied. 
The intervention was thus cost effective both before and 
after inclusion of future unrelated medical costs. How-
ever, the increase of the ICER with over 50% shows that 
the effect can be large. (See [46] for more details.)
Textbox 1: Future unrelated medical costs and the cost effec‑
tiveness of LCZ696 Most patients with chronic symptomatic 
heart failure with reduced ejection fraction are treated with 
angiotensin-converting enzyme inhibitors (ACEI) and beta-
blockers. When ACEI are not tolerated, patients may receive 
angiotensin receptor blockers. However, if patients remain 
symptomatic, ACEI should be replaced by the angiotensin 
receptor neprilysin inhibitor sacubitril/valsartan (LCZ696). 
A global health economic model was adopted to reflect the 
Dutch societal perspective, to determine the cost effective-
ness of LCZ696 in comparison to treatment with ACEI in 
adult patients with chronic heart failure with reduced left 
ventricular ejection fraction in the Netherlands, based on 
an average age of 75 years.
The analysis displayed a quality-adjusted life-year 
(QALY) gain from LCZ696 compared to ACEI of 0.33. 
With total incremental costs (excluding future unrelated 
medical costs) of €5839, the incremental cost-effective-
ness ratio (ICER) was estimated on €17,600 per QALY. 
The increased longevity of 0.39 life-year because of 
LCZ696 caused additional discounted medical costs, 
unrelated to heart failure, of €2950. The inclusion of 
future unrelated medical costs increased the ICER with 
€8891 (€2950/0.33) to €26,491 per QALY gained.
3  Future Non‑Medical Costs
In this section, we discuss future non-medical costs. As 
already mentioned in the introduction, these costs are only 
relevant for the societal perspective. We follow the same 
structure here as for the previous section, starting with the 
theoretical debates, following with empirical research.
3.1  Theoretical Debates
Some of the mathematical models highlighted above in the 
discussion of the inclusion of future medical costs have 
also played a key role in the debate on the inclusion of 
future non-medical costs. Generally, comparable conclu-
sions were drawn regarding the inclusion. For instance, 
in the welfare-optimizing decision rule derived from the 
model by Garber and Phelps [5], future non-medical costs 
could be included or excluded without affecting the rela-
tive ranking of cost effectiveness. This conclusion strongly 
depended on the restrictive assumptions underlying the 
model. Using less restrictive assumptions, Meltzer [6] 
found that the welfare-optimizing decision rule necessar-
ily includes future non-medical costs. Leaving these out 
would affect the relative ranking of cost effectiveness of 
alternatives, which could consequently lead to suboptimal 
decisions and outcomes.
In terms of internal consistency, it should be noted 
that Meltzer implicitly assumed that in cost-effectiveness 
analyses, utility measures are used that capture the full 
welfare benefits, also those of non-medical consumption 
and productivity (leisure). However, QALYs are intended 
to measure health-related quality of life. The internal con-
sistency rules, proposed by Nyman, specify that the ICER 
should only include costs for which the related benefits are 
also captured (or when these are causally related though 
do not yield additional benefits) [7]. One may wonder 
whether QALYs capture the benefits related to non-medical 
consumption.
From a theoretical point of view, QALY optimization 
would only be compatible with welfare maximization (with 
broader costs and benefits beyond health also implicitly con-
sidered) under strict assumptions rarely met in practice [47]. 
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Empirically, different views exist on what actual benefits are 
captured in the quality-of-life weights that are assigned to 
the health states. Standard gamble and time-trade-off exer-
cises are typically used to derive these weights. Although the 
most frequently used questionnaires used do not explicitly 
mention non-medical consumption [7], it is not clear what 
consumption level the respondents implicitly assume when 
answering the questions.
Some argue that people expect non-medical resource use 
to remain unaffected to the current level [9, 11]. Another 
view is that people at least consider the non-medical 
resource use needed to stay alive, such as daily food intake. 
Such assumptions have not been empirically verified. It is 
also good to emphasize that even if minimal consumption 
levels to stay alive are not considered by respondents in 
health-state valuations, they are still required to obtain the 
quality of life that is measured from the questionnaires and 
should thus be counted as a cost [10, 41]. This could also be 
stated for other non-medical consumption, which to a cer-
tain extent produces health in the same manner as medical 
care. Considerable gains in life expectancy in many Western 
countries were for example the result of interventions out-
side the healthcare sector (clean water, sewerage, healthier 
and safer foods, road safety) [48].
Available experiments suggest that respondents inconsist-
ently include impacts on productivity and leisure in health-
state valuations, if not explicitly requested to do so. The 
latter is uncommon in practice. The influence of spontaneous 
inclusion of these impacts on health-state valuations varied 
[49], although it was typically small and often insignifi-
cant, especially on average valuations, suggesting that these 
impacts would better be valued separately. Explicit instruc-
tions (to exclude these effects) could improve consistency in 
terms of what respondents include in health-state valuations.
Adarkwah and colleagues investigated the impact of 
instructions on including the impact of ill health on the 
utility of consumption and leisure in health-state valua-
tions [50]. Explicit instruction to consider this utility did 
not influence valuations. In contrast, spontaneous con-
sideration in the group without explicit instruction led to 
significantly lower valuations. From this, one could derive 
that currently the non-health benefits of interventions are 
not systematically captured through common health-state 
valuations. However, because relatively few studies have 
been performed in this area, with varying results, further 
research is needed to gain more insight into the extent to 
which people consider the broader welfare implications that 
result from ill health.
Besides being internally consistent, the information a 
cost-effectiveness analysis provides to decision makers 
should also be externally consistent; the information should 
entail the policy-relevant consequences of adopting an inter-
vention. In line with this, Lundin and Ramsberg argue that 
rather than following the QALY, which costs (and benefits) 
to include should be determined by the welfare theoretic 
foundations underlying a cost-effectiveness analysis [11]. 
This is related to the argument by Richardson and Olsen 
that the scope of the analysis should be consistent with the 
aims of the decision maker and preferences of society [9]. 
According to Nyman, because the aim of healthcare inter-
ventions is mainly to increase health, a focus on health-
related quality of life as an outcome would be sufficient [51]. 
These arguments, however, are more related to the issue of 
how to conceptualize the societal perspective appropriately 
[52] than to the specific issue of inclusion of future costs.
Nyman has later argued that the welfare implications of 
non-medical consumption and productivity (leisure) are 
already known to be positive, and can therefore be safely 
ignored. He argues that, unlike for medical consump-
tion, people can and do weigh benefits of non-medical 
consumption and production against its costs, and make 
deliberate and appropriate decisions whether to consume, 
and to work or enjoy leisure instead [17, 51]. Whether 
this is a sufficient argument to exclude these costs from 
evaluations remains to be seen, as the welfare effects may 
still differ between interventions (even if often positive). 
Meltzer also demonstrated that decisions will be affected 
when consumption or productivity are excluded when 
having an effect on welfare.
3.2  Empirical Research
Several studies have estimated net non-medical resource 
use, for inclusion in cost-effectiveness analyses [6, 41–45, 
53]. For this, productivity costs were estimated using the 
human capital approach (in economic evaluations, the 
friction cost approach sometimes is also used to calculate 
productivity costs in ‘normal’ life-years [4]). For con-
sumption, these studies used either data from household 
expenditure surveys [44, 53] or data on earnings to extract 
consumption costs as disposable income minus savings 
[42]. Age patterns of per-capita consumption and average 
earnings (as a proxy for productivity) were used for these 
estimates [6, 43–45].
Different views exist regarding how to handle transfer 
payments when estimating future consumption costs and 
productivity. Lee [14] argued that net resource use should be 
calculated by net dissavings, implying that not only earnings 
from productivity should be included, but also other sources 
of income such as private and public pension payments and 
asset income. This argument was refuted by Meltzer [15], 
explaining that transfer payments are not relevant when 
analyses are performed from a societal perspective. This is 
consistent with how transfer payments are treated in a tradi-
tional cost-effectiveness analysis from a societal perspective 
(as transfers not costs) [54].
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Net resource use (consumption minus production) is typi-
cally positive in younger ages, negative in middle ages, and 
again positive in older ages. This means that only in people 
of ‘working ages’ does production normally exceed consump-
tion. For example, it was shown that for the Danish population, 
production exceeded consumption from ages 24–62 years [42]. 
Other research found comparable patterns [41, 43–45]. The dif-
ference between age groups is typically owing to higher (paid) 
work force participation among younger people. Note that in 
these studies, data on household consumption were used to 
derive per-capita consumption but economies of scale within 
households were not addressed. Economies of scale can be 
important when the goal is to estimate the costs of non-medical 
consumption resulting from living longer because preventing 
death in a multi-person household would result in less addi-
tional consumption than preventing death in a single-person 
household. Additionally, to date, studies have not yet used 
the friction cost method when estimating production gains in 
life-years gained. This would likely result in lower productiv-
ity gains at a societal level from the prolonged life of patients 
(owing to the possibility of replacement), hence a less often 
negative net resource use. It needs to be noted that unpaid work 
is not accounted for in these calculations.
More generally, in comparison with the inclusion of the 
future medical costs, there is less experience with the inclu-
sion of future non-medical costs. An example of the differ-
ence in cost effectiveness when future non-medical costs are 
either included or excluded based on a Swedish study can 
be found in Textbox 2. Because of a change in the Swedish 
pharmacoeconomic guidelines, this study obtained ICERs 
both including and excluding future non-medical costs [55].4
The incremental cost-effectiveness ratio (ICER) 
[without future non-medical costs] was estimated to be 
€56,682 per QALY. Including future productivity gains 
(which were negligible owing to the fact that most life-
years are spent in retirement in this patient group) low-
ered the ICER with €457 to €56,225 per QALY. When 
consumption costs in added life-years were included, this 
increased the ICER with €28,642 to €84,867 per QALY 
gained.
Despite the relatively high ICER, the treatment was 
granted reimbursement by the Swedish authorities. (For 
more details see [55].)
4 Numbers are based on table IV in [55] and in euros. Consumption 
costs in this study comprised both medical and non-medical con-
sumption. Using the proportions from the original estimates [53], it 
can be derived that of the €28,642, the increase as a result of future 
non-medical consumption costs would be approximately €25,896 ((1-
(13,623/142,074))*28,642), and the increase as a result of future non-
medical costs would be €2746.
5 For an overview of country-specific pharmacoeconomic guidelines, 
see https ://tools .ispor .org/pegui delin es/.
Textbox 2: Future non‑medical costs and the cost effective‑
ness of pomalidomide Patients with multiple myeloma 
who have progressed following treatment with both bort-
ezomib and lenalidomide have a poor prognosis. In this 
late stage, patients are often left with best supportive care. 
Pomalidomide is an anti-angiogenic and immunomodula-
tory drug for the treatment of multiple myeloma.
The cost effectiveness was estimated of pomalido-
mide as an add-on to best supportive care in patients 
with relapsed and refractory multiple myeloma in Swe-
den, based on an average age of patients of 64 years. The 
analysis displayed a quality-adjusted life-year (QALY) 
gain from pomalidomide of 0.74 and increased longevity 
of 1.21 life-year.
4  Practical Relevance
4.1  Pharmacoeconomic Guidelines
Which costs are actually considered in a cost-effectiveness 
analysis largely depends on the requirements in country-spe-
cific pharmacoeconomic guidelines.5 These guidelines gen-
erally prescribe the inclusion of future related medical costs 
(typically referring to these as ‘direct medical costs’) in the 
reference case, the standard format for a cost-effectiveness 
analysis. However, they often pay no further attention to 
the inclusion of future unrelated medical costs or explicitly 
require the exclusion of these costs. In jurisdictions in which 
a societal perspective is adopted, it is generally required to 
include future productivity costs (or gains) and the future 
costs of non-medical consumption related to the intervention 
(such as informal care and traveling expenditures). Other 
non-medical consumption is rarely mentioned in the guide-
lines. Consistent with these prescriptions, empirical studies 
found that in practice, future unrelated medical costs and 
future non-medical consumption costs not related to the 
intervention are rarely included in economic evaluations 
[41, 56].
Some countries recently changed their guidelines regard-
ing the inclusion of future costs. For instance, Dutch guide-
lines, which prescribe adopting a societal perspective, tra-
ditionally did not require the inclusion of future unrelated 
medical costs. This changed in 2016, when inclusion of 
these costs became mandatory. However, still no specific 
attention is paid to future non-medical consumption that 
is not related to the intervention [57]. In 2013, Swedish 
guidelines, adopting a societal perspective, were changed to 
specifically (and uniquely) prescribe the inclusion of future 
costs as total consumption (medical and non-medical) minus 
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production in life-years gained [58]. However, the guidelines 
were changed after criticism was voiced from the public 
and patient advocacy groups on the inclusion of future costs 
[59]. It was stated that it would be investigated how these 
costs should be handled in the future [60, 61]. In the revised 
versions from 2015 [62] and 2017 [63], only the inclusion 
of future related medical costs and additional productivity in 
life-years gained is required and not future unrelated medi-
cal and consumption costs. In contrast, the second US Panel 
on Cost-Effectiveness in Health and Medicine in 2016 [64] 
recommended the inclusion of all future costs, contrary to 
the first US Panel in 1996 [28]. While the recommendations 
of the Panel are not official requirements, they have shown 
to be influential [65].
In the debates on the inclusion of future unrelated medi-
cal costs, the influential National Institute for Health and 
Care Excellence guidelines [66], which apply in England 
and Wales, are often discussed. These prescribe taking a 
healthcare perspective. To date, however, National Institute 
for Health and Care Excellence guidelines exclude future 
unrelated medical costs from the analysis. It has been argued 
that National Institute for Health and Care Excellence should 
change its guidelines in this context because the exclusion of 
future unrelated medical costs is inconsistent with the aims 
of the analysis [2, 20, 21, 27, 29]. Counterarguments mainly 
relate to ethical concerns regarding the potential distribu-
tional impact of including these costs [26, 29].
Summarizing, in general, guidelines still typically are 
silent or prescribe the exclusion of future unrelated medical 
costs and future non-medical costs not directly related to 
the treatment. However, first signs of adjustment towards 
inclusion of, at least, future unrelated medical costs appear 
to be showing. The inclusion of future non-medical costs 
not directly related to the treatment may follow, but seems 
more contested.
4.2  Ethical Concerns
As illustrated by the examples in the textboxes, the inclusion 
of future unrelated medical costs and future non-medical 
costs can have a substantial impact on final ICERs. Conse-
quently, including these costs in cost-effectiveness analy-
ses in practice may affect funding decisions. In general, the 
impact of the inclusion of these costs is larger when life-
years gained are spent in relatively poor health (implying a 
lower denominator and thereby increasing the ICER). Note 
that while the total number of life-years gained is relevant in 
terms of budget impact, it typically has a limited impact on 
the ICER. Further, even if the number of life-years gained 
is small, the impact of future costs can still be substantial.
Additionally, including future unrelated medical costs and 
future non-medical costs results in different decisions on what 
care to provide, and thus has distributional consequences. 
Including future unrelated medical costs may, for instance, dis-
favor interventions targeted at the elderly (because non-medical 
expenditures are typically higher at higher ages, which increases 
the impact of including future unrelated medical costs) and 
people already in ill health or with already higher healthcare 
expenditures. On the ground of such ethical concerns, it has 
been argued to exclude future costs from a cost-effectiveness 
analysis [4, 26, 29, 67]. Acknowledging the relevance of these 
issues, it has also been argued that ignoring real costs is not an 
appropriate or useful answer to ethical questions [3, 27, 68]. 
One may even wonder whether ignoring real opportunity costs, 
that will have consequences on others, is an ethical strategy. 
Furthermore, ignoring real costs endangers the credibility and 
usefulness of outcomes from a cost-effectiveness analysis [27]. 
Equity issues need to be dealt with, preferably based on all rel-
evant information in deliberative decision-making processes. 
In light of the information provided, decision makers may for 
instance wish to use a higher threshold for care focused on spe-
cific groups of patients [69].
The question of how to appropriately incorporate ethical 
concerns into the decision-making process is an important 
matter in this context. One method is through an appraisal 
phase in which ethical concerns are dealt with explicitly, while 
being fully informed on all relevant costs and effects [27]. 
This may also be facilitated by incorporating societal distri-
butional preferences into the ICER or threshold, by assigning 
higher weights or values to health gains for specific groups in 
the population [65]. Another option is to use a multi-criterion 
decision analysis. In this approach, formal methods are used 
to identify and score the various factors considered relevant 
to a decision [1]. All such methods do require initial inclusion 
of information on all relevant costs and benefits.
5  Discussion
5.1  Future Medical Costs
The theory and practical possibility of including future medi-
cal costs in a cost-effectiveness analysis has significantly 
developed over the past years. Most (relevant) economic 
models revealed that optimal outcomes require considering 
all current and future medical costs, regardless whether these 
are related or unrelated [6, 15, 16, 19]. Although some mod-
els yielded opposite results [5, 14], the assumptions underly-
ing these models are too restrictive to be relevant in practice. 
Furthermore, other arguments against the inclusion of future 
unrelated medical costs (e.g., future unrelated medical costs 
are not a necessary consequence of an intervention or that 
future unrelated treatments should be evaluated on their own) 
have been refuted [19, 20].
It has also been explained that projected benefits from 
interventions require the provision of future unrelated care 
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and that costs thereof should also be considered in economic 
evaluations to be internally consistent [7, 12]. Furthermore, 
external consistency requires both the benefits and costs of 
future unrelated care to be included for the analysis to be 
most informative for the decision maker. It has additionally 
been argued that ethical issues (e.g., inclusion may disadvan-
tage specific patient groups) should be dealt with explicitly 
and informedly, and cannot justify systematically ignoring 
real costs.
Most pharmacoeconomic guidelines nevertheless still do 
not require the inclusion of future unrelated medical costs. 
This may be because of some ‘status quo bias’, wish for 
intertemporal comparability of results, and practical con-
cerns about difficulties of estimating these costs. It may also 
simply reflect the fact that guidelines are normally based on 
well-established and accepted viewpoints, which implies they 
follow (with some lag) on from theoretical developments.
It must also be noted that it is not only the cost effec-
tiveness of the new intervention for which additional inclu-
sion of future unrelated medical costs would be relevant. 
Additionally, this issue matters for the determination of the 
threshold against which the cost effectiveness is judged. For 
instance, within a system with a fixed healthcare budget, 
when funding a new healthcare intervention implies displac-
ing health sector activity elsewhere, the threshold represents 
the cost effectiveness of displaced care. The future unrelated 
medical costs should also be considered in the estimates of 
the threshold to more accurately represent the opportunity 
costs. Recent estimates of such a threshold in the Nether-
lands illustrated how this can be achieved [70].
5.2  Future Non‑Medical Costs
For jurisdictions adopting a societal perspective in economic 
evaluations, with the aim to optimize societal welfare, future 
non-medical costs are relevant to consider as well [6]. This is 
typically not done in practice nor prescribed or encouraged 
in guidelines. Concerns about the benefits captured when 
quantifying outcomes in QALYs reiterated the debate on 
the appropriateness of including these costs because internal 
consistency requires that only costs are included when ben-
efits thereof are also included [7]. Several authors discussed 
the extent to which welfare implications beyond health are 
measured and valued in QALYs [49, 50].
A point that has not yet received any attention in the discus-
sion in this context is to what extent people take into account 
the non-medical benefits when they provide monetary valu-
ations of QALY gains. These valuations are usually obtained 
using willingness-to-pay exercises and are one possible source 
of determining the threshold value at which health technolo-
gies are considered too expensive [71]. Further research in this 
area is needed. If such research shows that relevant aspects 
of benefits beyond health are indeed not systematically and 
comprehensively measured and valued in current economic 
evaluations, one could take this to imply that the associated 
costs can also be ignored. However, if the aim is to improve 
overall societal welfare, a more appropriate response might 
be to investigate how the scope of economic evaluations can 
be broadened to include the relevant benefits as well as costs.
Although internal consistency is a fundamental premise 
(considering that all transactions have both a cost side and 
benefit side) [17], internal consistency is not a sufficient 
criterion. The information a cost-effectiveness analysis 
provides should also be externally consistent. It needs to 
inform the relevant decision maker by providing information 
on all relevant consequences of adopting an intervention. It 
can be argued that interventions in healthcare primarily aim 
to improve health-related quality of life. However, welfare 
implications beyond health (care budgets) can also be rele-
vant for decision makers. This is, by definition, true for deci-
sion makers who aim to optimize societal welfare, defined in 
a relevant welfarist or extra-welfarist approach [6].
One might also argue that decision makers in principle tak-
ing a healthcare perspective would not wish to be left com-
pletely ignorant about the ‘welfare externalities’ their decisions 
might have. In such cases, a separate account of broader societal 
impacts may be provided. In either case, the inclusion of future 
non-medical costs would be warranted. A two-perspective 
approach could facilitate a full account of impacts, while indi-
cating where these impacts fall. Recently, the second US Panel 
on Cost-Effectiveness in Health and Medicine argued in favor 
of using such a two-perspective approach, detailing impacts 
from both a healthcare perspective and from a broader soci-
etal perspective [64], as was proposed before [72]. With such 
an approach as standard, non-medical costs could systemati-
cally be included in economic evaluations in healthcare. This 
leaves open the possibility for decision makers to weight certain 
impacts more than others and to explicitly address distributional 
consequences related to the inclusion of specific elements.
However, given the questions regarding whether, how, 
and to what extent the benefits beyond health related to 
future non-medical costs are adequately captured in current 
economic evaluations, it would be premature to advise to 
simply include these costs. For now, it might be advisable to 
include these costs separately in a cost-effectiveness analy-
sis. Then, at least the decision maker is provided with more 
comprehensive information regarding societal costs that fol-
low from a new intervention.
6  Future Research
Regarding future unrelated medical costs, further research 
could be aimed at reducing practical objections in terms 
of difficulties in estimating future unrelated medial costs, 
by standardizing methods and estimates across and within 
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jurisdictions. This will improve both the applicability of 
inclusion and the comparability of outcomes. Translating 
the large body of research on the economics of aging into 
tools and reference tables that can be used by practitioners 
of a cost-effectiveness analysis seems one clear way for-
ward. Furthermore, estimates of future unrelated medical 
costs could be improved by taking into account changes in 
healthcare expenditures over time as presently these esti-
mates are typically based on the current standard of care.
For future non-medical costs, further research should be 
conducted regarding the question of whether relevant ben-
efits are already captured in current outcome measures, and, 
if not, how this could be assured. To facilitate inclusion, 
research is also required on the development and improve-
ment of methods for the estimation of future non-medical 
consumption costs. For instance, by accounting for econo-
mies of scale in household consumption and by investigating 
the relation between non-medical consumption and health 
status. Furthermore, research should focus on how to stand-
ardize estimation methods across jurisdictions applying the 
societal perspective, to broaden the applicability and com-
parability of outcomes.
7  Conclusion
When an intervention prolongs life, additional costs in the 
added life-years are incurred. To allow optimal decisions, 
both from a healthcare and societal perspective, including 
the additional related and unrelated medical costs in eco-
nomic evaluations is required. Knowledge on how to esti-
mate future (unrelated) medical costs has improved, also 
allowing inclusion in practice. Inclusion of these costs would 
presumably benefit most from lowering the practical difficul-
ties and the burden on the analyst of including these costs in 
a cost-effectiveness analysis, as well as guidelines prescrib-
ing or at least encouraging inclusion rather than prescribing 
exclusion.
For future non-medical costs, the conclusion is less clear. 
The benefits of future non-medical consumption and produc-
tivity may currently not be comprehensively and systemati-
cally included in a cost-effectiveness analysis. Therefore, the 
appropriate technique to include future non-medical costs 
requires further attention, both theoretically and empirically. 
Research in this area is encouraged. Ultimately, this should 
contribute to optimal decision making in healthcare to obtain 
the most favorable outcomes for society.
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